General Information of Drug (ID: DMJPR8M)

Drug Name
PMID25037917C58 Drug Info
Synonyms GTPL8520; BDBM50052641
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
91827366
TTD Drug ID
DMJPR8M
VARIDT Drug ID
DR01104

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LP-403812 DMIWMZY Discovery agent N.A. Investigative [2]
Drug(s) Targeting Dopamine transporter (DAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [3]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [4]
Methylphenidate DM7SJD6 Attention deficit hyperactivity disorder 6A05.Z Approved [5]
Modafinil DMYILBE Malignant glioma 2A00.0 Approved [6]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [7]
Ioflupane i-123 DMNARJT Parkinson disease 8A00.0 Approved [8]
DEXMETHYLPHENIDATE HYDROCHLORIDE DM8WBAH Attention deficit hyperactivity disorder 6A05.Z Approved [9]
Altropane DMO9WDS Attention deficit hyperactivity disorder 6A05.Z Approved [10]
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [11]
NAV5001 DMRSI1M Dementia 6D80-6D86 Phase 3 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [1]
Sodium-dependent proline transporter (SLC6A7) TT9LGO5 SC6A7_HUMAN Inhibitor [1]

References

1 Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3886-90.
2 Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter. Neurosci Lett. 2009 Feb 27;451(3):212-6.
3 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
4 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
5 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
10 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).